Результаты поиска

Seeking American Society of Clinical Oncology-Quality Oncology Practice Initiative (ASCO-QOPI) certification in a northern New England rural health system and cancer care network.

In 2006 following several years of preliminary study, the American Society of Clinical Oncology (ASCO) launched the Quality Oncology Practice Initiative (QOPI). This cancer-focused quality initiative evolved considerably over the next decade-and-a-half and is expanding globally. QOPI is undoubtedly the leading standard-bearer for quality cancer care and contemporary medical oncology practice. The program garners attention and respect among federal programs, private insurers, and medical oncology practices across the nation. The MaineHealth Cancer Care Network (MHCCN) has undergone expansive gr

First aid interventions by laypeople for acute oral poisoning.

BACKGROUND: Oral poisoning is a major cause of mortality and disability worldwide, with estimates of over 100,000 deaths due to unintentiona … ng acute oral poisoning patients, including but potentially not limited to activated charcoal (AC), emetics, cathartics, diluents, neutralizing agents and body positioning. DATA COLLECTION AND ANALYSIS: Two reviewers independently performed study selection, data collection and assessment. Primary outcomes of this review were incidence of mortality and ad …

Epidemiological profile of patients with malignant neoplasm admitted to a tertiary care center in India: a retrospective cross-sectional study.

BackgroundCancer poses a growing public health challenge in India, with significant urban-rural disparities in diagnosis and treatment. This study aimed to evaluate the epidemiological profile and treatment patterns of cancer patients in Rajasthan, focusing on differences in disease presentation, treatment modalities, and outcomes between urban and rural populations.MethodsA retrospective observational study was conducted at the National Institute of Medical Sciences and Research, Jaipur, including 1,366 histopathologically confirmed cancer patients admitted between January 2021 and December 2

Совпадение в полном тексте источника
… Supportive therapies Anti-emetics (45.97%), anti-inflammatory drugs (45.75%), antacids (42.45%), and antihistamines (36.31%) were the most commonly administered supportive therapies ( Table 4 ). These therapies were integral to improving patient quality of life during treatment. … Supportive therapy was frequently used, with anti-emetic, anti-inflammatory, and antacid drugs being the most popular. The widespread use of supportive therapy emphasizes the necessity of controlling cancer treatment side effects to improve patient quality of life ( 34 ). …

Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis.

BACKGROUND: Most cancer patients suffer from the pain of chemotherapy-induced nausea and vomiting (CINV). This meta-analysis was performed to evaluate the efficacy and safety of a regimen consisting of aprepitant, dexamethasone, and 5-HT3 receptor antagonists in the prevention and treatment of CINV. METHODS: A systematic literature search was conducted across multiple databases, including PubMed, EMbase, Cochrane Library, MEDLINE, CENTRAL, HEED, CNKI, Wanfang, and VIP, to identify randomized controlled trials (RCTs) investigating the use of triple therapy (aprepitant, 5-HT3 receptor antagonis

The safety and efficacy of a novel hypo-fractionated total marrow and lymphoid irradiation before allogeneic stem cell transplantation for lymphoma and acute leukemia.

PURPOSE: Total body irradiation (TBI) has been widely utilized as part of the conditioning regimen for hematopoietic stem cell transplantation (HSCT), but is associated with significant toxicities. Targeted TBI using helical Tomotherapy allows precise and homogeneous tumor coverage and excellent sparing of organs at risk. The purpose of this study was to evaluate the clinical outcomes of a novel hypo-fractionation strategy for patients receiving total marrow and involved lymphoid irradiation (TMLI) as part of the conditioning regimen before HSCT. METHODS AND MATERIALS: 61 patients (7 acute my

Совпадение в полном тексте источника
… Standard anti-emetic regimens were used and palifermin was not administered. Helical Tomotherapy planning Immobilization: Patients were positioned using a dedicated immobilization system developed by our radiotherapy technicians’ team to best fix the patients. … Supportive care Intravenous fluid support, and anti-emetics were prescribed 2 h before TMLI treatment. Non-steroidal anti-inflammatory drugs were given to patients with fever after radiotherapy. …

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

PURPOSE: This review is an update of the MASCC/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. METHODS: A systematic literature search was conducted using PubMed from June 1, 2015, through February 1, 2023. RESULTS: We identified 56 references (16 were duplications or invalid), leaving 40 manuscripts for this search. The panel classified level I evidence (three manuscripts) and level II evidence (14 manuscripts). High-dose chemotherapy and stem cell trans

CNS Вовлечение нескольких серий дел Myeloma-A и наррутический литературный обзор.

Фон: участие центральной нервной системы (ЦНС) в множественной миеломе (ММ) представляет собой экстрамуллярное проявление заболевания, которое часто является весьма сложным для врачей, поскольку неврологические симптомы могут легко перекликаться с симптомами, связанными с гиперкалкемией, уремией, высокой вязкостью крови или связанной с лечением нейропатией. Цели: Это ретроспективное исследование было проведено в Клиническом институте Фундэни в Бухаресте с целью выявления и систематического анализа ряда клинических случаев, диагностированных внематочным заболеванием. Методы: В период с 2019 по

Patient perceptions of symptoms and concerns during cancer chemotherapy: 'affects my family' is the most important.

BackgroundCancer chemotherapy is associated with a variety of side effects/adverse events. It is very important that patients adhere to the planned chemotherapy regimen, which necessitates a minimum of side effects and that these side effects be kept under control. We have investigated patients' concerns and symptoms during chemotherapy with the aim to seek solutions that will improve patients' quality of life during chemotherapy.MethodsForty-nine patients with malignant diseases on parenteral antineoplastic agents were sequentially enrolled in this study. These patients completed a questionna

Should oncologists trust cannabinoids?

Cannabis enjoyed a "golden age" as a medicinal product in the late 19th, early 20th century, but the increased risk of overdose and abuse led to its criminalization. However, the 21st century have witnessed a resurgence of interest and a large body of literature regarding the benefits of cannabinoids have emerged. As legalization and decriminalization have spread around the world, cancer patients are increasingly interested in the potential utility of cannabinoids. Although eager to discuss cannabis use with their oncologist, patients often find them to be reluctant, mainly because clinicians

Selinexor in relapsed/refractory multiple myeloma.

Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies, patients ultimately relapse. Selinexor is a first-in-class exportin-1 inhibitor with activity in these multiply relapsed and refractory patients. Although the current Food and Drug Administration (FDA) approval is for the doublet of Selinexor in combination with dexamethasone, ongoing clinical trials are evaluating a number of com

Совпадение в полном тексте источника
… Most patients will require multiple anti-emetic agents to properly manage these issues. This typically includes prophylactic use of steroids and 5-HT3 receptor antagonists. … Patients with pre-existing marrow compromise and high risk for nausea may benefit from aggressive prophylactic measures with growth factors and anti-emetics respectively. …

Оптимизация использования мелфлюфена (melphalan flufenamide) в реанимированных или рефрактных миеломах: рекомендации для клинической практики.

В настоящем докладе группа экспертов по миеломе, состоящая из нескольких экспертов, оценивает роль мелфлюфена (Melphalan flufenamide) в лечении пациентов с повторной или рефрактной множественной миеломой (RRMMM). На основе имеющихся данных приводятся рекомендации по управлению мелфлюфеном, управлению неблагоприятными явлениями и оптимальному отбору пациентов. Мелфлюфен, первый в классе пиптидный матрос, утверждается в Европейском союзе и Соединенном Королевстве в сочетании с дексаметазоном для лечения взрослых пациентов с множественной миеломой (ММ), которые получили по крайней мере three :: п

Incidence and Risk Factors of Chemotherapy-Induced Nausea and Vomiting Among Adult Cancer Patients at Mbarara Regional Referral Hospital: A Prospective Study.

BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) remains a significant and distressing adverse effect of cancer treatment, adversely affecting patients' quality of life. Despite well-established international guidelines for antiemetic prophylaxis, variability in CINV incidence and guideline adherence persists across different regions and healthcare settings, particularly in low- and middle-income countries (LMICs). OBJECTIVE: This study determined the incidence and associated factors of chemotherapy-induced nausea and vomiting (CINV) among adult cancer patients at Mbarara Regional

Политика и перспективы в отношении амбулаторных программ для аутологической трансплантации клеток и лечения иммуноэффективных клеток.

Высокодозированная химиотерапия с автоматической трансплантацией гематопоиетических клеток (AutoHCT) давно является комплексной формой лечения множественной миеломы и неходгкинской лимфомы. В прошлом 25 Многие учреждения сместили эту практику с госпитализации на one , которые могут быть выполнены в амбулаторном порядке, что приведет к экономии средств и повышению качества жизни пациентов. Недавно появившиеся методы лечения иммуноэффективных клеток (ИЭК) и расширение их масштабов приводят к изменению ландшафта лечения гематологовых и негематологических магнатов. Однако нынешние финансовые модел

Pharmacovigilance in oncology.

Background Side effects of cancer therapy are one of the most important issues faced by cancer patients during their illness. Pharmacovigilance, namely the science and activities aimed at monitoring the safety of drugs, is particularly important in oncology, due to the intrinsic biologic toxicity of antineoplastic agents, their narrow therapeutic windows, and the high doses and rigid timing of treatment regimens. Aim of the review To identify the main issues in carrying out an effective pharmacovigilance activity in oncology. Method We searched PubMed for articles about pharmacovigilance in re

Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program.

BackgroundHealthcare professionals are faced with the new challenges of preventing and managing drug-related problems (DRPs) with oral anticancer therapy (OAT): side-effects, drug-drug interactions (DDIs), non-adherence, or medication errors. This study aims to assess the impact of ONCORAL, a real-life multidisciplinary care plan for cancer patients based on community and hospital follow-up, for the first OAT cycle.MethodsA prospective cohort study was conducted between October 1, 2021 and October 1, 2022 including all outpatients starting OAT treatment. During the first OAT cycle, the program

Совпадение в полном тексте источника
… In 49% of cases, interventions were relayed to the oncologist ( n = 68), who then intervened in three-quarters of cases, for example by teleconsultation with the patient ( n = 11), prescription of additional support drugs such as anti-emetics ( n = 17), discontinuation of the OAT ( n = 7), or dose reduction … Coordination of the patient’s care pathway Seventy-eight NPIs concerned with coordination of the patient’s care pathway, including the community-hospital link, and enabling relay of information: for example, transferring an anti-emetic prescription to the community pharmacy, informing the community …

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.

Ixazomib is an investigational proteasome inhibitor that has shown preclinical activity in lymphoma models. This phase 1 study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics and preliminary activity of intravenous (IV) ixazomib in relapsed/refractory lymphoma patients who had received ⩾ 2 prior therapies. Thirty patients with a range of histologies received ixazomib 0.125-3.11 mg/m(2) on days 1, 8 and 15 of 28-day cycles. Patients received a median of two cycles (range 1-36). MTD was determined to be 2.34 mg/m(2). Most common drug-related ad

Совпадение в полном тексте источника
… All DLTs resolved after ixazomib dose modification or delay, and the use of supportive care (such as growth factor support, anti-emetics and hydration). … Of those experiencing grade ⩾3 AEs, 2/6 patients with neutropenia required growth factor support, and 0/4 with thrombocytopenia required platelet transfusions; 3/3 patients with diarrhea were administered with anti-emetics (5-HT3 antagonists) or anti-diarrheal agents. …

Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.

Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. CINV typically manifests during two well-defined time periods (acute and delayed phases). The acute phase is the first 24 hours after chemotherapy and is largely managed with 5-hydroxytryptamine 3 receptor antagonists. The delayed phase, a 5-day at-risk period during which patients are not often in direct contact with their health care provider, remains a significant unmet medical need. Neurokinin-1 (NK-1) receptor antagonists have demonstrated protection against acute and del

Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.

INTRODUCTION: Antibody-drug conjugates (ADC) have emerged as an important part of systemic treatment across disease sites. To date, there is … d as clinically relevant and further investigated to help develop optimal strategies related to antiemetics.

Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model.

IntroductionThe COVID-19 pandemic has challenged healthcare systems worldwide over the last few months, and it continues to do so. Although some restrictions are being removed, it is not certain when the pandemic is going to be definitively over. Pandemics can be seen as a highly complex logistic scenario. From this perspective, some of the indications provided for palliative radiotherapy (PRT) during the COVID-19 pandemic could be maintained in the future in settings that limit the possibility of patients achieving symptom relief by radiotherapy. This paper has two aims: (1) to provide a summ

Randomized Study of enterade® to Reduce Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.

High-dose chemotherapy frequently causes injury to the gastrointestinal mucosa, resulting in diarrhea. The purpose of the current study was to assess the tolerability and efficacy of enterade® in reducing ≥ grade 2 diarrhea (G2D) in association with high-dose melphalan followed by autologous stem cell transplantation (ASCT). We conducted a prospective, double blinded, multi-center trial in which 114 subjects were randomized to receive enterade® or placebo twice daily during the transplant hospitalization. Gastrointestinal toxicities (nausea, vomiting, oral mucositis and dysphagia) resulted in